Behl, D., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Farrington, L. C., Crysler, O. V., … Schilsky, R. L. (2023). Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. 122–122).

Behl, Deepti, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Laura Catherine Farrington, Oxana V. Crysler, Elie G. Dib, et al. “Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, 41:122–122, 2023.

Behl D, Rothe M, Mangat PK, Garrett-Mayer E, Farrington LC, Crysler OV, et al. Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 122–122.

Behl, Deepti, et al. “Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. 122–122.

Behl D, Rothe M, Mangat PK, Garrett-Mayer E, Farrington LC, Crysler OV, Dib EG, Duvivier HL, Hall MJ, Salmon JS, Alese OB, Marr AS, Ngirailemesang I, Polavaram L, Thota R, Yang ES-H, O’Lone R, Grantham GN, Halabi S, Schilsky RL. Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 122–122.